Phase 4 psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Phase 4 is a registry phase value. Studies of an intervention that is already approved for some use, run to learn more about its use in practice. A phase describes how a study is designed, not what it found.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 65 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Ketamine | 65 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 9 | 14% |
| Not yet recruiting | 2 | 3% |
| Enrolling by invitation | 1 | 2% |
| Active, not recruiting | 3 | 5% |
| Completed | 28 | 43% |
| Terminated | 6 | 9% |
| Suspended | 1 | 2% |
| Withdrawn | 3 | 5% |
| Status not reported | 12 | 18% |
Countries
Country is taken from the study's linked research site. 4 of 65 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 35 | 54% |
| Canada | 4 | 6% |
| Australia | 3 | 5% |
| China | 3 | 5% |
| Brazil | 2 | 3% |
| Egypt | 2 | 3% |
| United Kingdom | 2 | 3% |
| Taiwan | 2 | 3% |
| Argentina | 1 | 2% |
| Germany | 1 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 10 |
| 2020 to 2023 | 22 |
| 2015 to 2019 | 17 |
| 2010 to 2014 | 11 |
| Before 2010 | 5 |
Study design
- 65 interventional and 0 observational studies.
- Median planned or actual enrolment is 48 participants (range 1 to 1,806, across 62 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 40 |
| Suicidal thoughts | 11 |
| Pain and headache | 2 |
| Trauma and PTSD | 1 |
| Anxiety | 1 |
| Other substance use | 1 |
| Cancer and end of life | 1 |
| Healthy volunteers | 1 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07680140 | Biomarker-Guided Antidepressant Selection | Recruiting | Phase 4 | United States | 2026-07 |
| NCT07139106 | Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | Not yet recruiting | Phase 4 | United States | 2026-02 |
| NCT07369102 | Esketamine With or Without Integration Therapy for Treatment-Resistant Depression | Recruiting | Phase 4 | Puerto Rico | 2026-02 |
| NCT07120477 | Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities | Recruiting | Phase 4 | Brazil | 2026-01 |
| NCT06968624 | Ketamine for Postherpetic Neuralgia With Depression | Not yet recruiting | Phase 4 | Not reported | 2025-06 |
| NCT07053345 | A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression | Completed | Phase 4 | South Korea | 2025-06 |
| NCT06414356 | The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD | Recruiting | Phase 4 | United States | 2024-10 |
| NCT06278779 | Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression | Recruiting | Phase 4 | Australia | 2024-06 |
| NCT06077487 | Ketamine-assisted Therapy for Advanced GI Cancer | Terminated | Phase 4 | United States | 2024-05 |
| NCT06213324 | Neural Circuit Effects of Ketamine in Depression | Recruiting | Phase 4 | United States | 2024-01 |
| NCT06103760 | Positioning of Esketamine Treatment in the Real-world Management of Depression | Recruiting | Phase 4 | Australia | 2023-10 |
| NCT06060210 | Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion | Completed | Phase 4 | Egypt | 2023-10 |
| NCT05554627 | VA Aripiprazole vs Esketamine for Treatment Resistant Depression | Withdrawn | Phase 4 | United States | 2023-10 |
| NCT06034821 | Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan | Enrolling by invitation | Phase 4 | United States | 2023-10 |
| NCT05698394 | Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth | Active, not recruiting | Phase 4 | China | 2023-09 |
| NCT05997134 | Three Regimens of Ketamine Infusion in Complex Regional Pain Syndrome | Status not reported | Phase 4 | Egypt | 2023-08 |
| NCT05506462 | An EEG Study of Intravenous Ketamine for Major Depression Disorder | Status not reported | Phase 4 | Not reported | 2023-01 |
| NCT05615948 | Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression | Completed | Phase 4 | United States | 2022-12 |
| NCT05450432 | Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | Recruiting | Phase 4 | United States | 2022-10 |
| NCT05487885 | Anhedonia, Development, and Emotions: Phenotyping and Therapeutics | Completed | Phase 4 | United States | 2022-07 |
| NCT05950711 | Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study | Active, not recruiting | Phase 4 | United States | 2022-03 |
| NCT05045378 | Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression | Completed | Phase 4 | Taiwan | 2022-03 |
| NCT05026203 | Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression | Completed | Phase 4 | Thailand | 2021-09 |
| NCT04829318 | A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment | Completed | Phase 4 | Argentina | 2021-04 |
| NCT04578938 | Ketamine + Cognitive Training for Suicidality in the Medical Setting | Active, not recruiting | Phase 4 | United States | 2021-03 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase not applicable